Gajanan Bhat

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi et al. · Journal of Clinical Oncology · 2015 · 547 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase II Safety and Clinical Comparison With Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

Daniel S. Berman, Jamshid Maddahi, Balaji Tamarappoo et al. · Journal of the American College of Cardiology · 2012 · 206 citations

Medicine, Cardiology, Radiology +16

A Phase <scp>II</scp> trial of Belinostat ( <scp>PXD</scp> 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

Francine M. Foss, Ranjana H. Advani, Madeleine Duvic et al. · British Journal of Haematology · 2014 · 190 citations · Full text

Medicine, Oncology, Pharmacology +16

Poziotinib in Non–Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Xiuning Le, Robin Cornelissen, Marina Chiara Garassino et al. · Journal of Clinical Oncology · 2021 · 154 citations · Full text

Medicine, Oncology, Pharmacology +17

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

Xiuning Le, Jonathan W. Goldman, Jeffrey Clarke et al. · Journal of Clinical Oncology · 2020 · 95 citations

Medicine, Oncology, Pharmacology +15